#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Charles Dougherty Email
CEO . Vivasc Therapeutics
How to contact Charles Dougherty
Join and see Charles's contact info for free!Current Roles
Employees:
2Revenue:
$201kAbout
Vivasc Therapeutics is an early stage, pre-clinical cardiac drug development company. We are utilizing the proprietary Cardiac Targeting Peptide (CTP) platform technology to deliver various cargo exclusively to cardiomyocytes in a non-invasive manner. We are actively seeking: Joint development partners for our lead compound, CTP-amio, for the treatment of arrhythmias (atrial fibrillation and ventricular tachycardia) Partners to use CTP as a platform vector to deliver other therapeutic cargo (oligonucleotides, peptides, proteins, drugs, nanoparticles, stem cell therapies, etc.) exclusively to cardiomyocytesVivasc Therapeutics Address
2403 Sidney StPittsburgh, PA